USPTO Examiner PALLAY MICHAEL B - Art Unit 1617

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18609954MULTI-LAYERED POLYMER FILM FOR SUSTAINED RELEASE OF AGENTSMarch 2024February 2025Allow1110YesNo
18606877Pharmaceutical Complex for Radioprotection, Preparation Method, and Applications thereofMarch 2024May 2025Abandon1421NoNo
18602676ADIPOSE TISSUE MATRICESMarch 2024April 2025Abandon1310NoNo
18581460Treatment of Vomiting and Nausea with Minimum Dose of OlanzapineFebruary 2024April 2025Allow1310NoNo
18411935Method of Preventing and Treating COVID-19 InfectionJanuary 2024April 2025Abandon1510NoNo
18405543Compacted Hemostatic Cellulosic AggregatesJanuary 2024July 2024Allow700YesNo
18506204ACTIVE AGENT-CONTAINING MATRIX PARTICLES AND PROCESSES FOR MAKING SAMENovember 2023January 2025Abandon1410NoNo
18491407C-Met Modulator Pharmaceutical CompositionsOctober 2023January 2025Abandon1510NoNo
18243740RECTAL ADMINISTRATION OF ROFLUMILAST FOR THE TREATMENT OF CROHN'S DISEASESeptember 2023May 2024Abandon820NoNo
18454612METHODS OF USING EHMT2 INHIBITORS IN TREATING OR PREVENTING BLOOD DISORDERSAugust 2023January 2025Abandon1701NoNo
18343324PHARMACEUTICAL COMPOSITIONS OF PROTAC COMPOUNDS AND USES THEREOFJune 2023April 2025Allow2231YesNo
18336288USE OF CANNABINOIDS IN TREATING ANTI-DEPRESSANT-INDUCED FEMALE SEXUAL DYSFUNCTIONJune 2023January 2025Abandon1910NoNo
18304306USE OF VERAPAMIL FOR THE TREATMENT OF SARS-COV-2 INDUCED COVID-19April 2023January 2024Allow920YesNo
18303082VISCOSITY-REDUCING EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONSApril 2023November 2024Abandon1810NoNo
18126901TOPICAL THERAPEUTIC FORMULATIONSMarch 2023December 2024Allow2120NoNo
18113963COMPOSITIONS AND METHODS FOR TREATING CANKER SORESFebruary 2023April 2025Allow2630NoNo
18095478HEAT STABLE HYALURONIC ACID COMPOSITIONS FOR DERMATOLOGICAL USEJanuary 2023November 2024Abandon2210NoNo
18003644METHODS OF TREATMENT FOR A KIDNEY DISEASEDecember 2022July 2025Allow3000NoNo
18007787PLASMA KALLIKREIN INHIBITORSDecember 2022June 2025Allow3000NoNo
17926284A TOPICAL ANTIMICROBIAL COMPOSITIONNovember 2022August 2023Allow810YesNo
17921426COMPOSITION FOR TREATING AND/OR PREVENTING VESTIBULODYNIAOctober 2022March 2024Allow1610YesNo
17974231COMPOSITIONS AND FORMULATIONS INCLUDING CABAZITAXEL AND HUMAN SERUM ALBUMINOctober 2022June 2024Allow2010NoNo
17961961OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONSOctober 2022November 2024Allow2630YesNo
17953407BIORESORBABLE METAL ALLOY AND IMPLANTSSeptember 2022August 2024Allow2210YesNo
17933071VISCOSITY-REDUCING EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONSSeptember 2022January 2023Allow410NoNo
17943691Dihydromyricetin Hot Melt Extrusion Formulations and Methods for Forming ThemSeptember 2022February 2025Allow2921NoNo
17939348NICOTINE PARTICLESSeptember 2022March 2024Allow1810NoNo
17814567THERMO-KINETIC MIXING FOR PHARMACEUTICAL APPLICATIONSJuly 2022February 2024Allow1910NoNo
17724078CHRYSEOBACTERIUM INSECT INHIBITORY MICROBIAL COMPOSITIONS AND METHODS OF MAKING AND USINGApril 2022September 2024Allow2930YesNo
17717922MODIFIED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING DEFERIPRONEApril 2022February 2024Allow2231YesNo
17717913MODIFIED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING DEFERIPRONEApril 2022February 2024Allow2231YesNo
17702731METHOD AND DEVICE TO TRAP ACARIDSMarch 2022January 2024Abandon2201NoNo
17761652METHOD FOR MANUFACTURING DISPERSION OF ULTRAFINE PARTICLES OF POORLY SOLUBLE SUBSTANCEMarch 2022April 2025Abandon3701NoNo
17694571DIHYDROMYRICETIN NANOEMULSION FORMULATIONS AND METHODS FOR FORMING THEMMarch 2022June 2024Abandon2711NoNo
17638821Temperature-Sensitive Hydrogel Composition for Preventing Tissue Adhesion, and Preparation Method ThereforFebruary 2022March 2025Abandon3601NoNo
17597974Poly(Beta-Thioester) Polymers and Polymeric NanoparticlesJanuary 2022March 2025Allow3801YesNo
17631637LIQUID ORAL CARE COMPOSITIONJanuary 2022March 2025Abandon3701NoNo
17581591EXTRACELLULAR MATRIX (ECM) HYDROGEL AS A SUBMUCOSAL FLUID CUSHIONJanuary 2022April 2025Allow3910YesNo
17628830SUBSTITUTED N-PHENYL-N-AMINOUARCILS AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL AGENTSJanuary 2022February 2025Abandon3701NoNo
17578669TOPICAL COMPOSITIONS AND METHODS OF USE THEREOFJanuary 2022October 2024Abandon3301NoNo
17597604PARTICLES, PHARMACEUTICAL COMPOSITION, AND METHOD FOR PRODUCING PARTICLESJanuary 2022April 2025Abandon3911NoNo
17625408CAPSULE FOR COSMETICSJanuary 2022December 2024Allow3610YesNo
17570253FORMULATIONS OF L-ORNITHINE PHENYLACETATEJanuary 2022October 2023Abandon2110NoNo
17568452METHODS OF PREVENTING AND TREATING COVID-19 INFECTIONJanuary 2022April 2023Abandon1620NoNo
17559027LIP PRODUCT FORMULATION, APPLICATOR, AND METHOD FOR MAKING SAMEDecember 2021June 2023Allow1800NoNo
17559372Compacted Hemostatic Cellulosic AggregatesDecember 2021September 2023Allow2111NoNo
17559453FORMULATIONS OF L-ORNITHINE PHENYLACETATEDecember 2021September 2023Abandon2101NoNo
17619627PLANT VITALIZING AGENT CONTAINING EXOGENOUS ELICITOR AND ENDOGENOUS ELICITOR AND USE THEREOFDecember 2021April 2025Allow4020NoNo
17457176ANTIBIOFILM FORMULATIONSDecember 2021December 2024Allow3611NoNo
17531430CANNABINOID DOSAGE FORMSNovember 2021October 2024Allow3530YesNo
17527581NUTRACEUTICAL FORMULATION FOR POLYCYSTIC OVARY SYNDROMENovember 2021April 2025Allow4121YesNo
17520787NOVEL USE OF SODIUM DICHLOROISOCYANURATE (NaDCC) AND A PHARMACEUTICAL FORMULATION PREPARED THEREFROMNovember 2021January 2024Allow2611NoNo
17510692Finished Fibrous Structures and Methods of Their Use and PreparationOctober 2021October 2022Abandon1210NoNo
17509478GOLD NANO-DELIVERY SYSTEM FOR PAIN AND CANCER THERAPYOctober 2021December 2023Abandon2620YesNo
17510330PROCESS FOR THE PREPARATION OF DRUG LOADED MICROPARTICLESOctober 2021November 2023Allow2511NoNo
17509487GOLD NANO-DELIVERY SYSTEM FOR PAIN AND CANCER THERAPYOctober 2021February 2024Abandon2720YesNo
17604858TREATMENT OF VASCULAR AND LYMPHATIC DISEASEOctober 2021February 2024Allow2810NoNo
17505307C-Met Modulator Pharmaceutical CompositionsOctober 2021July 2022Abandon910NoNo
17594360HERBICIDAL COMPOUNDSOctober 2021February 2025Abandon4001NoNo
17499221Wound Dressings and Applications ThereofOctober 2021January 2024Allow2711NoNo
17489071METHOD OF ENHANCING THE EFFICACY AND STABILITY OF INGREDIENTS IN SUSPENSIONSSeptember 2021December 2023Abandon2711NoNo
17593701FUNGICIDE FORMULATIONS WITH REDUCED CRYSTAL GROWTHSeptember 2021May 2025Allow4421NoNo
17480616CHEMICALS WHICH ALTER THE PRODUCTION OF METABOLITES IN CULTIVATED PLANTSSeptember 2021November 2024Abandon3801NoNo
17474816SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASESSeptember 2021November 2024Abandon3810NoNo
17472162Composition For Enhancing Protein StrengthSeptember 2021January 2024Allow2821YesNo
17471518EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONSSeptember 2021June 2025Abandon4501NoNo
17408111ALL-IN-ONE FIXED-DOSE COMBINATION FOR TREATING HELICOBACTER PYLORI INFECTIONAugust 2021November 2023Allow2721NoNo
17406025EPIGENETIC MODIFICATION OF FUNGI AND USES THEREOFAugust 2021September 2024Allow3711YesNo
17444809MATERIALS AND METHODS FOR STOPPING RESPIRATORY VIRUS INFECTIONSAugust 2021December 2023Abandon2811NoNo
17381294METHOD FOR REDUCING SKIN SENSITIZATION OF AN ASENAPINE-CONTAINING PATCHJuly 2021November 2023Abandon2710NoNo
17381705Sorafenib particles and uses thereofJuly 2021July 2023Abandon2421NoNo
17305851MULTI-LAYERED POLYMER FILM FOR SUSTAINED RELEASE OF AGENTSJuly 2021December 2023Allow2920YesNo
17375814METHOD FOR PREPARING A LIPOSOMAL COMPOSITION COMPRISING LATANOPROST, AND THE PHARMACOLOGICALLY ACTIVE LIPOSOMAL COMPOSITION FOR OPHTHALMOTHERAPY PREPARED BY THIS METHODJuly 2021June 2022Allow1120NoNo
17373544SYSTEMS AND METHODS FOR USE OF CHLORINE DIOXIDE IN CULTIVATION AND POST-HARVEST APPLICATIONSJuly 2021February 2025Allow4341YesNo
17351453ANTIMICROBIAL COATINGS FOR MEDICAL IMPLEMENTS AND MEDICAL DEVICESJune 2021August 2023Allow2511NoNo
17350520METHODS OF PREVENTING AND TREATING COVID-19 INFECTIONJune 2021October 2023Allow2820NoNo
17346867COMPOSITIONS AND METHODS TO REDUCE DICAMBA VOLATILITY AND PROVIDE PLANT ESSENTIAL NUTRIENTSJune 2021April 2024Allow3441NoYes
17346872METHOD FOR PRODUCING A FIBRIN-BASED BIOARTIFICIAL, PRIMARILY ACELLULAR CONSTRUCT, AND THE CONSTRUCT ITSELFJune 2021August 2024Allow3831NoNo
17342859PHARMACEUTICAL FORMULATION CONTAINING GLYCOPYRROLATE AND INDACATEROL MALEATEJune 2021October 2022Abandon1621NoNo
17341213COATED DRUG COMPOSITIONS AND METHODS OF PREPARING THE SAMEJune 2021April 2024Allow3421NoNo
17332098METHODS AND COMPOSITIONS FOR TREATING SEPSISMay 2021April 2024Abandon3521NoNo
17327729STABILIZED MICROCAPSULES, METHOD OF THEIR PREPARATION AND USES THEREOFMay 2021June 2024Allow3731NoNo
17294820PARAQUAT FORMULATIONMay 2021March 2025Allow4620YesNo
17242612HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS FOR TREATING AGING-RELATED CONDITIONSApril 2021July 2023Abandon2611YesNo
17289711TREATMENT OF EXPOSURE TO CHLORINE GAS WITH SCOPOLAMINEApril 2021August 2023Abandon2710NoNo
17234112FORMULATION OF CALCIUM CHANNEL BLOCKERS FOR TREATMENT OF SARS-COV-2 INDUCED COVID-19 AND OTHER RESPIRATORY VIRUSES THROUGH PULMONARY DELIVERYApril 2021May 2024Abandon3730NoNo
17221532MEK1/2 INHIBITOR-LOADED MICROPARTICLE FORMULATIONApril 2021May 2024Abandon3731YesNo
17278291SUBSTITUTED PHENYLPROPENYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL APPLICATIONSMarch 2021August 2024Abandon4101NoNo
17197204ORAL DRUG DOSAGE FORM COMPRISING DRUG IN THE FORM OF NANOPARTICLESMarch 2021February 2025Allow4750NoNo
17180917COMPOSITION FOR SUBMUCOSAL INJECTION AND PREPARATION METHOD THEREOFFebruary 2021March 2023Allow2501NoNo
17165002USE OF CANNABINOIDS IN TREATING ANTI-DEPRESSANT-INDUCED FEMALE SEXUAL DYSFUNCTIONFebruary 2021March 2023Allow2540YesYes
17163119Ophthalmic Formulations and Uses ThereofJanuary 2021March 2024Abandon3821YesYes
17262902OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONSJanuary 2021November 2024Allow4630YesNo
17148262TREATMENT OF VOMITING AND NAUSEA WITH MINIMUM DOSE OF OLANZAPINEJanuary 2021November 2023Allow3421YesNo
17138507Thin Emulsion Base for CosmeticsDecember 2020August 2023Allow3120NoNo
17126715METHODS OF TREATING COVID-19 INFECTIONDecember 2020June 2021Allow620YesNo
17104081PYRAZOLE DERIVATIVES AS MALT1 INHIBITORSNovember 2020February 2024Allow3901NoNo
16953674METHODS OF PREVENTING AND TREATING COVID-19 INFECTIONNovember 2020August 2022Abandon2121NoNo
16952789METHODS FOR PREVENTION AND TREATMENT OF PRESSURE ULCERS CAUSED BY ISCHEMIA USING CONTACT VASODILATORSNovember 2020August 2023Abandon3351YesNo
17072207ADIPOSE TISSUE PRODUCTS AND METHODS OF PRODUCTIONOctober 2020August 2024Abandon4630NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PALLAY, MICHAEL B.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
19
Examiner Affirmed
16
(84.2%)
Examiner Reversed
3
(15.8%)
Reversal Percentile
25.9%
Lower than average

What This Means

With a 15.8% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
49
Allowed After Appeal Filing
8
(16.3%)
Not Allowed After Appeal Filing
41
(83.7%)
Filing Benefit Percentile
16.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 16.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner PALLAY, MICHAEL B - Prosecution Strategy Guide

Executive Summary

Examiner PALLAY, MICHAEL B works in Art Unit 1617 and has examined 770 patent applications in our dataset. With an allowance rate of 53.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner PALLAY, MICHAEL B's allowance rate of 53.6% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by PALLAY, MICHAEL B receive 2.27 office actions before reaching final disposition. This places the examiner in the 77% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by PALLAY, MICHAEL B is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +37.7% benefit to allowance rate for applications examined by PALLAY, MICHAEL B. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 21.0% of applications are subsequently allowed. This success rate is in the 16% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 30.9% of cases where such amendments are filed. This entry rate is in the 37% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 16.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 23% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 58.7% of appeals filed. This is in the 28% percentile among all examiners. Of these withdrawals, 59.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 71.2% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 57% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.3% of allowed cases (in the 80% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.